替莫唑胺
前药
安普克
药品
癌症研究
体内
药理学
抗药性
二甲双胍
颠倒
胶质母细胞瘤
合成致死
医学
化学
程序性细胞死亡
细胞
正面反馈
体外
化疗
DNA修复
厌氧糖酵解
药物发现
糖酵解
自噬
非正面反馈
DNA损伤
反馈回路
细胞存活
下调和上调
机制(生物学)
生物
PI3K/AKT/mTOR通路
作者
Wenjie Feng,Rui Yang,翁畅,Chen Li,Wanrui Shi,Yuehua Chen,Yang Yang,Yi Liu,Pengfei Ge,Hao Zhang
摘要
Glioblastoma (GBM), one of the most lethal human cancers, faces a major therapeutic challenge due to drug resistance. Temozolomide (TMZ), a standard first‐line drug for clinical GBM treatment, benefits only a subset of patients, leaving an urgent need for strategies that can restore its efficacy. Herein, we propose that cuproptosis, a recently identified regulated cell death (RCD), is capable of reversing TMZ resistance in GBM. We design copper‐TMZ (Cu‐TMZ) prodrugs, assembled via the coordination of Cu 2+ with TMZ and, in optimized formulations, co‐loaded with metformin (MET) as an AMPK activator, to exploit cuproptosis for overcoming TMZ resistance. Upon glutathione‐triggered disassembly, the prodrugs release Cu + and TMZ, inducing mitochondrial proteotoxic stress and initiating a self‐amplifying cuproptosis loop characterized by ATP depletion, AMPK‐p53 activation, and glycolysis inhibition. Beyond self‐reinforcement, cuproptosis directly potentiates TMZ activity by suppressing drug efflux, impairing DNA repair, and aggravating metabolic and redox stress. Both in vitro and in vivo experiments demonstrate that Cu‐TMZ/MET prodrugs markedly restore TMZ responsiveness and suppress TMZ‐resistant GBM progression. More broadly, this study illustrates how RCD pathways can be engineered into therapeutics to convert drug resistance into vulnerability, highlighting a generalizable strategy for improving the efficacy of frontline chemotherapy in otherwise intractable cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI